Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, M.
Right arrow Articles by Sano, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, M.
Right arrow Articles by Sano, K.

Stroke, Vol 20, 362-366, Copyright © 1989 by American Heart Association


ARTICLES

Effects of a new thyrotropin-releasing hormone derivative on behavioral changes after focal cerebral ischemia in rats

M Yamamoto, A Tamura, T Kirino, M Shimizu and K Sano
Department of Pharmacology, Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan.

We observed the effects of a new thyrotropin-releasing hormone derivative, YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L- histidyl-L-prolinamide dihydrate), on behavioral changes in rats for 3 weeks after focal cerebral ischemia. Under halothane anesthesia, the left middle cerebral artery was occluded via a transretro-orbital approach. YM-14673 was administered just after the operation and once a day for 3 weeks. Neurologic deficits, including hemiplegia and abnormal posture, and disturbance of passive avoidance learning were present in solvent-treated control rats for the entire 3 weeks. YM-14673 at 0.1 or 0.3 mg/kg i.p. or 1 mg/kg p.o. significantly accelerated the recovery of neurologic deficits and ameliorated cognitive disturbance compared with the solvent-treated controls although the drug at 0.1 and 0.3 mg/kg i.p. did not influence the size of the ischemic infarct. YM-14673 mitigated the behavioral disturbances in this model of chronic focal cerebral ischemia. We also discuss the suitability of this model for the evaluation of drugs.


This article has been cited by other articles:


Home page
StrokeHome page
B. Winter, B. Bert, H. Fink, U. Dirnagl, and M. Endres
Dysexecutive Syndrome After Mild Cerebral Ischemia?: Mice Learn Normally but Have Deficits in Strategy Switching
Stroke, January 1, 2004; 35(1): 191 - 195.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
K. Hattori, H. Lee, P. D. Hurn, B. J. Crain, R. J. Traystman, A. C. DeVries, and B. G. Lyeth
Cognitive Deficits After Focal Cerebral Ischemia in Mice Editorial Comment
Stroke, August 1, 2000; 31(8): 1939 - 1944.
[Abstract] [Full Text] [PDF]